Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.68 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27206195 | 1.00 | GLP1R (0.68) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL26482660 | 0.92 | GLP1R (0.67) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL28650725 | 0.92 | GLP1R (0.69) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL24338674 | 0.92 | GLP1R (0.69) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL22936415 | 0.90 | GLP1R (0.67) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL24265545 | 0.90 | GLP1R (0.59) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL24330242 | 0.90 | GLP1R (0.59) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL29974969 | 0.90 | GLP1R (0.59) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL29574129 | 0.90 | GLP1R (0.59) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL30151557 | 0.90 | GLP1R (0.59) | GLP1RCYP2C8KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981666-B2 | GLP-1 receptor agonist and composition and use thereof | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-05-14 | — | — | US | disclosed |
| EP-4361145-A1 | GLP-1 RECEPTOR AGONIST AND COMPOSITION AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-20240116906-A1 | GLP-1 Receptor Agonist and Composition and Use Thereof | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| US-20220213072-A1 | METABOLITES OF GLP1R AGONISTS | PFIZER INC. (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2022078152-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213072-A1 | METABOLITES OF GLP1R AGONISTS | GLP1R, GCGR, GIPR | GLP1R 1/4885CYP2C8 2089/4885KCNH2 4192/4885 |
| US-11981666-B2 | GLP-1 receptor agonist and composition and use thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885CYP2C8 1861/4885KCNH2 3438/4885 |
| US-20240116906-A1 | GLP-1 Receptor Agonist and Composition and Use Thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885CYP2C8 1861/4885KCNH2 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.